Latest news with #Avastin
Bloomberg
3 days ago
- Business
- Bloomberg
Pfizer's Braftovi Doubles Survival in Advanced Colorectal Cancer
A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, data that could change how physicians treat a particularly deadly form of the disease. Adding Pfizer's Braftovi to a cocktail of cancer medicines helped patients with a certain genetic mutation live a median of 30 months, according to data presented at the American Society of Clinical Oncology meeting Friday. Patients given standard treatment, a combination of chemotherapy and the Roche Holding AG drug Avastin, lived for 15 months at the median.
Reuters
5 days ago
- Business
- Reuters
Health Rounds: HIV pill improves diabetic eye disease without injections
May 28 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here.) An inexpensive pill for treating HIV could become an alternative to injections for diabetic eye disease, a small study suggests. 'An oral drug that improves vision in diabetic macular edema (DME) would be a game changer because it would be more convenient for patients than frequent, often monthly, injections into the eye,' study leader Dr. Jayakrishna Ambati of the University of Virginia said in a statement. At the start of the study, 24 patients in Brazil with DME were randomly assigned to receive Viiv Healthcare's oral antiviral drug Epivir (lamivudine) or a placebo for four weeks, to be followed by a standard injection of Roche's (ROG.S), opens new tab Avastin (bevacizumab) into the clear gel-like area that fills the eye between the lens and retina. After that initial four weeks, the ability to read letters on an eye chart had improved by 9.8 letters, or about 2 lines on the eye chart, in the lamivudine group, while it had decreased by 1.8 letters in the placebo group. Four weeks after the Avastin injection, the lamivudine recipients had improved by 16.9 letters, more than 3 lines on the chart, while the group that got just Avastin improved by only 5.3 letters. The HIV drug inhibits an early step in the inflammatory process that leads to DME, the researchers explained in a report published on Tuesday in the Cell Press journal Med, opens new tab. That mechanism of action is different from existing treatments, 'so we could also develop combination therapies,' Ambati said. While the results suggest that lamivudine may work both with and without Avastin injections, the Viiv drug alone could be life changing for patients in regions with limited access to specialty doctors or who are unable to afford or travel to monthly eye appointments, Ambati said. 'A $20-a-month or even cheaper oral pill that improves vision as much as or more than therapy with injections into the eye that cost up to $2,000 per month could be transformative both for patients and the healthcare system,' Ambati said. Researchers have come a step closer to designing GLP-1 drugs for weight loss that don't cause nausea, according to a report in Cell Metabolism, opens new tab. In experiments in mice with the GLP-1 drug semaglutide – the main ingredient in Novo Nordisk's ( opens new tab weight-loss drug Wegovy – the researchers identified the nerve cells in the brain stem that control the medicine's effects on appetite and weight and distinguished those from brain cells that contribute to the nausea. After determining which nerve cells were activated by the drug, they next found a way to stimulate these cells without administering the drug itself. The result was that the mice ate less and lost weight, just as they did when treated with semaglutide, but without nausea-related behavior. 'This suggests that these nerve cells control the beneficial effects of semaglutide,' study leader Júlia Teixidor-Deulofeu, a PhD student at Sahlgrenska Academy at the University of Gothenburg, said in a statement. 'If we can target the treatment there, we may be able to maintain the positive effects while reducing side effects.' When mammography is negative in women with dense breasts, MRI is superior to ultrasound for double-checking that no early-stage cancers have been missed, researchers reported in The Lancet, opens new tab. Women with dense breasts face increased risks of breast cancer, but mammograms are less effective for detecting early-stage cancer in these individuals because the dense tissue can hide tumors, the researchers explain. Doctors often advise them to follow a negative mammogram with an MRI or ultrasound exam, but it has not been clear whether one is better than the other for this purpose. More than 9,000 UK women with dense breasts and a negative mammogram, ages 50 to 70, were randomly assigned to undergo various supplemental screening techniques. The cancer detection rate was 0.4% with ultrasound, 1.7% with MRI, and 1.9% with mammography using an intravenous dye. The authors acknowledge that while the scans can detect additional small cancers, it's not clear whether finding those early tumors will reduce the number of deaths due to breast cancer. Further study is needed to establish the risk of over-diagnosis and to estimate the cost-benefit ratio of implementing a supplemental imaging strategy for breast cancer screening, they said. (To receive the full newsletter in your inbox for free sign up here)
Yahoo
15-05-2025
- Business
- Yahoo
Avastin (Bevacizumab) Market Research Report 2025: Epidemiology, Pipeline Analysis, Insights & Forecasts 2019-2024, 2024-2029F, 2034F
Key player operating in the avastin (bevacizumab) market is Roche Holding AG. North America was the largest region in the avastin (bevacizumab) market in 2024. The regions covered in avastin (bevacizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the avastin (bevacizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Avastin (Bevacizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to Avastin (Bevacizumab) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the growth during the historical period can be attributed to factors such as regulatory approvals, rising cancer prevalence, clinician adoption, expanding indication approvals, and favorable reimbursement growth during the forecast period is driven by increased awareness, earlier diagnosis, biosimilar competition, the rise of personalized medicine, improved healthcare accessibility, and a growing focus on precision medicine. Key trends for the forecast period include the rise of combination therapies, a shift towards outpatient care, patient-centric treatment models, increased adoption of targeted therapies, and ongoing product increasing prevalence of cancer is expected to drive the growth of the avastin (bevacizumab) market in the coming years. Cancer encompasses a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. The rising incidence of cancer can be attributed to factors such as aging populations, lifestyle changes, and advancements in detection methods. Avastin, a monoclonal antibody, treats cancer by inhibiting VEGF, preventing the formation of blood vessels that supply oxygen and nutrients to tumors, thereby impeding tumor growth. For instance, the American Cancer Society reported that in 2022, approximately 1.9 million new cancer cases and 609,360 cancer-related deaths were anticipated in the United States, equivalent to about 1,670 deaths daily. This rising cancer burden is a significant driver of the avastin market's growth of the Avastin (bevacizumab) market is expected to be propelled by rising healthcare expenditure. Healthcare expenditure encompasses the total spending on health-related goods and services, including personal care, preventive measures, and public health activities, aimed at enhancing health outcomes. This increase is driven by factors such as an aging population, the prevalence of chronic diseases, advancements in medical technology, high drug prices, inefficient payment systems, and a growing demand for healthcare services. Elevated healthcare expenditure facilitates greater access to Avastin through improved insurance coverage, thereby broadening its market reach and patient utilization. For example, a report by the UK's Office for National Statistics in May 2024 highlighted a 5.6% nominal increase in total healthcare expenditure from 2022 to 2023, compared to a 0.9% growth rate in 2022. Additionally, long-term health and social care spending rose by 2.8% in real terms in 2022. This trend reflects how increasing investment in healthcare systems supports the accessibility and growth of innovative treatments like Avastin, further driving the market forward.A key trend shaping the avastin (bevacizumab) market is the development of biosimilars to provide cost-effective alternatives and improve access to cancer treatments. Biosimilars, highly similar in structure, function, and efficacy to Avastin, are transforming oncology care by offering affordable options, particularly in resource-constrained settings. For example, in October 2022, Amneal Pharmaceuticals launched ALYMSYS (bevacizumab-maly), a biosimilar referencing Avastin, in the U.S. This VEGF inhibitor is indicated for various cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, renal cell carcinoma, and gynecologic cancers, demonstrating the potential of biosimilars to enhance treatment (bevacizumab) is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), effectively inhibiting angiogenesis - the process by which new blood vessels are formed to supply tumors with oxygen and nutrients. It is commonly used in conjunction with chemotherapy to treat various cancers, including colorectal, lung, kidney, and primary dosages of avastin (bevacizumab) are 100 mg and 400 mg. The 100 mg dosage form is used to treat a range of cancers by preventing the growth of blood vessels that nourish tumors. Its applications include non-squamous non-small cell lung cancer, recurrent glioblastoma, cervical cancer, colorectal cancer, ovarian cancer, proliferative diabetic retinopathy, malignant glioma, neurofibromatosis, pancreatic cancer, among others. These products are distributed through various channels such as direct tender, hospital pharmacies, retail pharmacies, and online pharmacies. End users include hospitals, cancer care centers, home healthcare providers, academic and research institutes, and avastin (bevacizumab) market consists of sales of intravenous (iv) formulations, and bevacizumab injection. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the Topics Covered: 1. Executive Summary2. Avastin (Bevacizumab) Market Characteristics3. Avastin (Bevacizumab) Market Biologic Drug Characteristics3.1. Molecule Type3.2. Route of Administration (ROA)3.3. Mechanism of Action (MOA)3.4. Safety and Efficacy4. Avastin (Bevacizumab) Market Trends and Strategies5. Avastin (Bevacizumab) Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market6. Global Avastin (Bevacizumab) Growth Analysis and Strategic Analysis Framework6.1. Global Avastin (Bevacizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)6.2. Analysis of End Use Industries6.3. Global Avastin (Bevacizumab) Market Growth Rate Analysis6.4. Global Avastin (Bevacizumab) Historic Market Size and Growth, 2019-2024, Value ($ Billion)6.5. Global Avastin (Bevacizumab) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)6.6. Global Avastin (Bevacizumab) Total Addressable Market (TAM)7. Global Avastin (Bevacizumab) Market Pricing Analysis & Forecasts8. Avastin (Bevacizumab) Market Segmentation8.1. Global Avastin (Bevacizumab) Market, Segmentation by Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion 100 Mg 400 Mg 8.2. Global Avastin (Bevacizumab) Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Non Squamous Non-Small Cell Lung Cancer Recurrent Glioblastoma Cervical Cancer Colorectal Cell Cancer Ovarian Cancer Proliferative Diabetic Retinopathy Malignant Glioma Neurofibromatosis Pancreatic Cancer Other Applications 8.3. Global Avastin (Bevacizumab) Market, Segmentation by Distribution channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Direct Tender Hospital Pharmacy Retail Pharmacy Online Pharmacy Other Distribution Channels 8.4. Global Avastin (Bevacizumab) Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Hospitals Cancer Supportive Centers Home Healthcare Academic and Research Institutes Other End Users 9. Global Avastin (Bevacizumab) Market Epidemiology of Clinical Indications9.1. Drug Side Effects9.2. Incidence and Prevalence of Clinical Indications10. Avastin (Bevacizumab) Market Regional and Country Analysis10.1. Global Avastin (Bevacizumab) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion10.2. Global Avastin (Bevacizumab) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Axios
12-05-2025
- Business
- Axios
Biotech company Genentech pledges to create 400 jobs in Holly Springs
Genentech, a biotechnology company based in South San Francisco, could add 400 jobs in the Wake County town of Holly Springs after agreeing to an incentives deal with North Carolina. Why it matters: Holly Springs continues to be one of the major hot spots for biotech expansions in the country. Amgen, Fujifilm Diosynth, Seqiris and Janssen Pharmaceuticals have together already invested billions of dollars to expand biotech manufacturing to the town in recent years. State of play: The investment comes a month after Genentech's parent company, the Swiss drug maker Roche, said it would invest heavily in the U.S. in response to the Trump administration's tariffs, Reuters reported. Genentech produces a variety of drugs treating cancers and rare diseases, like Avastin for colorectal cancer and Herceptin for breast cancer. Driving the news: North Carolina approved a Job Development Investment Grant for Genentech Monday morning worth up to $9.8 million in tax cuts for the company — if it meets hiring and investment goals. Zoom in: The state said Genentech would invest $700 million into a new, 700,000-square-foot facility in Holly Springs.
Yahoo
11-04-2025
- Business
- Yahoo
Tempest seeks strategic alternatives as cash runs out for Phase 3 trial
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Tempest Therapeutics is seeking a buyer or partner, saying Wednesday it has hired financial advisers to 'advance its promising clinical stage programs and maximize stockholder value,' as the California-based biotechnology company prepares a liver cancer drug for late-stage testing. Tempest didn't set a deadline for reaching a deal, and doesn't plan to disclose the nature of its talks or deal evaluation process until the company has 'determined that further disclosure is appropriate or necessary.' That cancer drug, called amezalpat, poses a 'rare opportunity for a partner,' according to CEO Stephen Brady, who pointed to supportive data as well as the drug being cleared for Phase 3 trials. Tempest ended 2024 with just over $30 million in cash and equivalents, which it cautioned was not enough to fully fund a Phase 3 trial. Brady said 'the capital markets have been unavailable' for the company to raise more money. The biotech sector has struggled through a funding drought as initial public offerings and secondary share sales alike have declined. Tempest had set out to find some additional funding, but with its market capitalization hovering around its cash holdings, a secondary offering wasn't a likely avenue of raising more cash. The company completed a one-for-13 share consolidation on Tuesday, just as world markets were battered by the imposition of global tariffs, many now watered down, by President Donald Trump. Tempest dodged some of the volatility of being a young biotech on the stock market, going public through a reverse merger with the University of Michigan spinout Millendo Therapeutics after the company had clinical setbacks. Millendo's corporate shell had formed through a different reverse merger with a company that worked in female infertility, called OvaScience, which also struggled in clinical studies. Tempest may have a promising asset in amezalpat. When combined with Roche's Tecentriq and Avastin in the first-line setting, amezalpat reduced the risk of death by 35% in people with hepatocellular carcinoma compared with the two Roche drugs by themselves. (The pairing of Tecentriq and Avastin are one of two recommended first-line treatments for hepatocellular carcinoma.) That Phase 2 trial also found people who received the amezalpat combination lived a median of 21 months, compared with 15 months for those getting only Tecentriq and Avastin. Based on that data, the Food and Drug Administration granted amezalpat fast-track designation as well as orphan drug status, both of which will ease some regulatory requirements. Tempest had also been cleared to begin its Phase 3 trial. Recommended Reading Athira exploring strategic alternatives after Alzheimer's failure Sign in to access your portfolio
